Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

M2699

Sigma-Aldrich

Marimastat

≥98% (HPLC), solid, MMP inhibitor

Sinonimo/i:

BB2516, (2S,3R)-N4-[(1S)-2,2-Dimethyl-1-[(methylamino)carbonyl] propyl]-N1,2-dihydroxy-3-(2-methylpropyl)butanediamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C15H29N3O5
Numero CAS:
154039-60-8
Peso molecolare:
331.41
Numero MDL:
MFCD00866242
Codice UNSPSC:
12352200
ID PubChem:
329817950
NACRES:
NA.77

product name

Marimastat, ≥98% (HPLC)

Livello qualitativo

100

Saggio

≥98% (HPLC)

Forma fisica

solid

Solubilità

DMSO: ≥20 mg/mL

Condizioni di spedizione

wet ice

Temperatura di conservazione

−20°C

Stringa SMILE

CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C

InChI

1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
OCSMOTCMPXTDND-OUAUKWLOSA-N

Informazioni sul gene

Applicazioni

Marimastat has been used as an inhibitor of:
  • metalloproteinase 2/9 (MMP2/9), to study its effects on exercise-mediated interleukin-6 (IL-6) release in mice
  • metalloproteinase, to determine protease activity in Pseudomonas aeruginosa cultures
  • metalloproteinase 10 (MMP10), to study its effect on monoclonal antibody H3 binding to MMP10

Azioni biochim/fisiol

Marimastat is a broad spectrum matrix metalloprotease (MMP) inhibitor

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

TAPI-2 InSolution, ≥97%, 10 mM aqueous solution, inhibitor of matrix metalloproteinases and TACE (TNF-α convertase; ADAM17)

Sigma-Aldrich

5.09612

TAPI-2

TAPI-1 InSolution, ≥97%, inhibits MMPs and TACE

Sigma-Aldrich

579053

TAPI-1

Ecotin, E. coli A potent, broad range inhibitor of serine proteases.

Sigma-Aldrich

330200-M

Ecotin, E. coli

MMP-13 Substrate, Fluorogenic A quenched fluorescence substrate for MMP-13 (collagenase-3; kcat/Km = 1.09 x 10⁶ M⁻¹s⁻¹).

Millipore

444235-M

MMP-13 Substrate, Fluorogenic

D-(−)-Ribose suitable for cell culture, BioReagent

Sigma-Aldrich

R9629

D-(−)-Ribose

TAPI-0 ≥95% (HPLC)

Sigma-Aldrich

SML1292

TAPI-0

Varespladib ≥98% (HPLC)

Sigma-Aldrich

SML1100

Varespladib

Vincent E de Meijer et al.
PloS one, 5(6), e11256-e11256 (2010-07-02)
Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their enzymatic degradation, primarily by matrix metalloproteinases (MMPs). The effect of pharmacological MMP inhibition on fibrogenesis, however, is largely unexplored. Inflammation is considered a prerequisite and
Aura D Urribarri et al.
Gut, 63(10), 1658-1667 (2014-01-18)
Polycystic liver diseases (PCLDs) are genetic disorders characterised by progressive bile duct dilatation and/or cyst development. Their pathogenesis is a consequence of hyperproliferation, hypersecretion and microRNA alterations in cholangiocytes. Here we evaluate the role of matrix metalloproteases (MMPs) in the
Timothy W Failes et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 13(10), 2974-2982 (2006-12-16)
We report a potential means of selectively delivering matrix metalloproteinase (MMP) inhibitors to target tumour sites by use of a bioreductively activated Co(III) carrier system. The carrier, comprising a Co(III) complex of the tripodal ligand tris(methylpyridyl)amine (tpa), was investigated with
Victor A Levin et al.
Journal of neuro-oncology, 78(3), 295-302 (2006-04-26)
Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas. A total of 162 patients with intracranial
M Ohshima et al.
Journal of dental research, 89(11), 1315-1321 (2010-08-27)
The underlying mechanism and the therapeutic regimen for the transition of reversible gingivitis to irreversible periodontitis are unclear. Since transforming growth factor (TGF)-β has been implicated in differentially regulated gene expression in gingival fibroblasts, we hypothesized that TGF-β signaling is
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.